• main image

    Avant-Garde Therapy for Intractable Diseases

    The World’s First PEGylated Bilirubin Technology

Leadership

arrow_forward

Our Technology

arrow_forward

Patients

arrow_forward

Our Identity

Bilix is established based on the world’s first PEGylated bilirubin platform technology to produce numerous “First in Class” in anti-inflammatory and “Best in Class” in cancer therapy drugs in addition to achieving other business platform such as contrast agents for cancer diagnostics, and theranostics.

Read more

Ingenious Platform with PEGylated Bilirubin

BRIXELLE Platform is based on a proprietary technology and can be used to cure many intractable inflammatory diseases. It also can be developed into a highly potent and less toxic anti-cancer drug delivery system and other theranostics applications.

Latest news

23 Biotech Companies Pitch for Funding at Saudi Arabia’s LSIF 2026

On:

23 Companies, Eight Countries, One Grand Winner The Life Sciences Innovation Forum, known as LSIF, is the investment platform of the Riyadh Global Medical Biotechnology Summit (RGMBS 2026). This year’s

Read More →

[인터뷰] 日 신약 피칭대회 우승 빌릭스, ‘빌리루빈 신약’으로 신장손상 예방·치료 도전

On:

“김명립 대표, 쇼난 아이파크 ‘이노베이션 타이거’ 우승…페길화·전합성 기술로 약물화”,“심장수술 관련 급성신손상 예방 임상2a상 진행…2027년 후속 데이터 확보 목표”,“100억~150억원 시리즈C 투자유치 중…2028년 기술이전·2029년 IPO 겨냥”, [더바이오 이영성 기자] 심장수술이 끝나도 환자의 회복을

Read More →

빌릭스, 사우디 ‘2026 생명과학 혁신포럼’서 대상 수상

On:

리야드 글로벌 의료바이오기술 서밋 투자 프로그램서 높은 평가, [더바이오 최성훈 기자] 국내 신약 개발기업인 빌릭스(Bilix)가 사우디아라비아에서 열린 ‘생명과학 혁신포럼’에서 대상을 받았다. 사우디아라비아 리야드 글로벌 의료바이오기술 서밋(RGMBS)은 최근 리야드에서 ‘2026 생명과학

Read More →

Collaborators

We work closely with our collaborators in all aspects of drug development and commercialization including research organizations, clinical development entities, hospitals, intellectual property experts, patient advocate groups, and governments. Our ambition is to improve patient health and care. If you are interested in collaborating with us, please contact us.